Do analysts rate AADI or IPSC?

Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 95.47%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Do analysts prefer PRTC or AADI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, PRTC or AADI?

Aadi Bioscience has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Aadi Bioscience $25.07M 4.13 -$65.76M -$2.35 N/A

Do analysts recommend AADI or KMDA?

Kamada has a consensus price target of $12.00, suggesting a potential upside of 60.00%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, AADI or KMDA?

Kamada has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07M 4.13 -$65.76M -$2.35 N/A Kamada $180.46M 2.39 $20.20M $0.35 21.43

Is AADI or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Aadi Bioscience's net margin of -246.06%. Kamada's return on equity of 7.73% beat Aadi Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Kamada 11.21% 7.73% 5.41%

Aadi Bioscience (AADI) Competitors

$4.19 -0.11 (-2.56%)

As of 07/2/2026

Compare

AADI vs. IPSC, EPRX, PRTC, KMDA, and ENTA

Should you buy Aadi Bioscience stock or one of its competitors? MarketBeat compares Aadi Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aadi Bioscience include Century Therapeutics (IPSC), Eupraxia Pharmaceuticals (EPRX), PureTech Health (PRTC), Kamada (KMDA), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "pharmaceutical products" industry.

How does Aadi Bioscience compare to Century Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Century Therapeutics	Neutral

Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 95.47%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Aadi Bioscience. Century Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A
Century Therapeutics	$109.16M	4.01	-$9.58M	-$1.14	N/A

Century Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Century Therapeutics' return on equity of -49.89% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Century Therapeutics	N/A	-49.89%	-37.42%

Summary

Century Therapeutics beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A

In the previous week, Eupraxia Pharmaceuticals' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Neutral
Aadi Bioscience	Neutral

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Eupraxia Pharmaceuticals beats Aadi Bioscience on 9 of the 14 factors compared between the two stocks.

How does Aadi Bioscience compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

0.0% of PureTech Health shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PureTech Health has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. PureTech Health's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Aadi Bioscience has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A

PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, PureTech Health had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for Aadi Bioscience. PureTech Health's average media sentiment score of 0.30 beat Aadi Bioscience's score of 0.00 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Neutral
Aadi Bioscience	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PureTech Health beats Aadi Bioscience on 8 of the 12 factors compared between the two stocks.

How does Aadi Bioscience compare to Kamada?

Aadi Bioscience (NASDAQ:AADI) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.21% compared to Aadi Bioscience's net margin of -246.06%. Kamada's return on equity of 7.73% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Kamada	11.21%	7.73%	5.41%

Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Kamada has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Kamada has a consensus price target of $12.00, suggesting a potential upside of 60.00%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A
Kamada	$180.46M	2.39	$20.20M	$0.35	21.43

In the previous week, Kamada had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Kamada and 0 mentions for Aadi Bioscience. Kamada's average media sentiment score of 0.15 beat Aadi Bioscience's score of 0.00 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Kamada	Neutral

Summary

Kamada beats Aadi Bioscience on 13 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Enanta Pharmaceuticals' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Aadi Bioscience	Neutral

Enanta Pharmaceuticals currently has a consensus target price of $20.29, suggesting a potential upside of 34.25%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Enanta Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Enanta Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Aadi Bioscience has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.73	-$81.89M	-$2.59	N/A
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A

Enanta Pharmaceuticals has a net margin of -89.56% compared to Aadi Bioscience's net margin of -246.06%. Enanta Pharmaceuticals' return on equity of -64.04% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

Enanta Pharmaceuticals beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$103.48M	$791.45M	$7.18B	$12.47B
Dividend Yield	N/A	4.84%	2.66%	6.51%
P/E Ratio	-1.84	1.66	28.02	24.70
Price / Sales	4.13	127.53	537.00	97.28
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.98	8.17	10.96	6.46
Net Income	-$65.76M	-$3.71M	$3.57B	$337.01M
7 Day Performance	0.72%	2.59%	2.12%	1.69%
1 Month Performance	-4.77%	4.41%	5.25%	3.81%
1 Year Performance	110.55%	49.43%	33.29%	23.90%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.19 -2.6%	N/A	+110.6%	$103.48M	$25.07M	N/A	40	High Trading Volume
IPSC Century Therapeutics	1.4069 of 5 stars	$2.45 +1.7%	$4.75 +93.9%	+333.9%	$434.65M	$109.16M	N/A	170	High Trading Volume
EPRX Eupraxia Pharmaceuticals	2.011 of 5 stars	$6.61 +0.3%	$18.00 +172.3%	+22.4%	$428.48M	N/A	N/A	29	Positive News
PRTC PureTech Health	0.1249 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	News Coverage
KMDA Kamada	4.9582 of 5 stars	$7.34 -0.3%	$12.00 +63.5%	-3.3%	$423.24M	$181.68M	20.97	360	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. IPSC, EPRX, PRTC, KMDA, and ENTA

How does Aadi Bioscience compare to Century Therapeutics?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Summary

How does Aadi Bioscience compare to PureTech Health?

Summary

How does Aadi Bioscience compare to Kamada?

Summary

How does Aadi Bioscience compare to Enanta Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. IPSC, EPRX, PRTC, KMDA, and ENTA

How does Aadi Bioscience compare to Century Therapeutics?

Do institutionals and insiders believe in AADI or IPSC?

Which has more risk & volatility, AADI or IPSC?

Does the media favor AADI or IPSC?

Do analysts rate AADI or IPSC?

Which has better earnings & valuation, AADI or IPSC?

Is AADI or IPSC more profitable?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Is EPRX or AADI more profitable?

Do analysts prefer EPRX or AADI?

Which has more volatility and risk, EPRX or AADI?

Which has preferable earnings & valuation, EPRX or AADI?

Does the media refer more to EPRX or AADI?

Do institutionals & insiders believe in EPRX or AADI?

Summary

How does Aadi Bioscience compare to PureTech Health?

Do institutionals and insiders hold more shares of PRTC or AADI?

Is PRTC or AADI more profitable?

Which has better earnings & valuation, PRTC or AADI?

Which has more volatility & risk, PRTC or AADI?

Does the media refer more to PRTC or AADI?

Do analysts prefer PRTC or AADI?

Summary

How does Aadi Bioscience compare to Kamada?

Do insiders and institutionals hold more shares of AADI or KMDA?

Is AADI or KMDA more profitable?

Which has more risk & volatility, AADI or KMDA?

Do analysts recommend AADI or KMDA?

Which has preferable valuation and earnings, AADI or KMDA?

Does the media prefer AADI or KMDA?

Summary

How does Aadi Bioscience compare to Enanta Pharmaceuticals?

Do insiders & institutionals hold more shares of ENTA or AADI?

Does the media favor ENTA or AADI?

Do analysts prefer ENTA or AADI?

Which has more volatility and risk, ENTA or AADI?

Which has better valuation and earnings, ENTA or AADI?

Is ENTA or AADI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools